This report provides a complete overview of all commercial beverage consumption trends, latest market developments and an economic mood indicator What is the current market landscape and what is changing? Economic statistics published during June cast new light on the scale of the 2008-09 economic downturn, which was deeper than previously estimated, with the subsequent recovery also slightly weaker. What are the key drivers behind recent market changes? Average weekly earnings growth rose to 1.3% in the three months to April, mainly due to higher bonus payments. The labor market otherwise appears to have been relatively stable during 2013. What makes this report unique and essential to read? Designed for clients who want to understand the latest trends in the United Kingdom beverage industry and want more detail and analysis on this data. United Kingdom Quarterly Beverage Tracker report is ideal for benchmarking total market vs retail audit data and is an essential tool for keeping up-to-date with the latest industry and market developments Key Features and Benefits Readers are provided with a summary snap shot table showing category growth in Q22013vsQ22012, together with 2012 actual volumes, 2013 forecast volumes and projected growth An economic mood indicator, completed by local consultant, examines (on a scale of one to five) whether confidence levels in the industry are better or worse than the previous quarter, whether net prices are rising or falling and how Private Label products have performed versus the rest of the market. Selected retail pricing data is given for the most recent quarter and the previous four quarters, enabling analysis of price movements. Key highlights of the last quarter’s commercial beverage performance are identified and the key market drivers examined Volumes for Q2 2013vs Q22012, full year 2012, moving annual totals (MAT) and 2013 forecasts are provided for each individual beverage category, together with supporting text on quarterly performance and forecast assumptions. More granular data is provided for the Carbonates category, with data split by regular vs low calorie, and by key flavours.
United Kingdom travel guide
E-mail Address London (PRWEB) September 23, 2013 PharmaPoint: Chronic Myeloid Leukemia (CML) – United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, aPharmaPoint: Chronic Myeloid Leukemia (CML) – United Kingdom Drug Forecast and Market Analysis to 2022a. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patientsa survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the launch of Bosulif and Iclusig will act as driving forces of market growth, it will not be enough to compensate for erosion of Gleevec and Sprycel sales once their generic equivalents hit the market. Scope -Overview of the CML including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. -Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis. -Sales forecast for the top drugs in the UK from 2012-2022. -Analysis of the impact of key events as well the drivers and restraints affecting the UK CML market. Reasons to buy -Understand and capitalize by identifying products that are most likely to ensure a robust return -Stay ahead of the competition by understanding the changing competitive landscape for CML -Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential -Make more informed business decisions from insightful and in-depth analysis of drug performance -Obtain sales forecast for drugs from 2012-2022 in the UK Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 5.3.6 Minor Therapeutic Classes 57 6 Opportunity and Unmet Need 59 6.1 Overview 59 6.2 Unmet Need: A Drug that Can Cure CML 60 6.3 Unmet Need: Lower Annual Cost of Therapy 61 6.4 Unmet Need: Treatments for Patients Who Have Primary Resistance to or are Refractory to TKIs 62 6.5 Unmet Need: More Efficacious Treatments for AP and BP CML 62 6.6 Unmet Need: Therapies with Fewer Chronic Side Effects 63 6.7 Unmet Need: Better Compliance from Patients on Long-Term Oral Therapy 63 6.8 Unmet Need: Methods of Determining the Optimal Therapy for a Patient 64 6.9 Opportunity: Exploration into Discontinuation Therapy 64 6.10 Opportunity: Companion Devices to Enhance Patient Adherence to Oral Therapy 65 6.11 Opportunity: Therapies with BCR-ABL Independent MOAs 65 6.12 Opportunity: Extended-Release Formulations of TKIs 66 6.13 Opportunity: Biomarkers to Identify the Optimal Therapy for a Given Patient 66 7 Pipeline Assessment 67 7.2 Innovative Early-Stage Approaches 67 7.2.1 Project 1: The Wnt Signaling Pathway 69 7.2.2 Project 2: Jak2 Inhibitors 70 7.2.3 Project 3: Grb-2 71 7.2.4 Case Study: Smoothened Inhibitors 72 8 Market Outlook 73 9.4.1 Diagnosed CML patients 88 9.4.2 Drug-treated Patients on X Line of Therapy 89 9.4.3 Drugs Included in Each Therapeutic Class 89 9.4.4 Launch and Patent Expiry Dates 89 9.4.5 General Pricing Assumptions 90 9.4.6 Compliance Assumptions for Oral TKIs 90 9.4.7 Individual Drug Assumptions 91 9.4.8 Generic Erosion 93 9.4.9 Pricing of New Market Entrants 93 9.5 Physicians and Specialists Included in this Study 94 9.6 Survey of High Prescribing Physicians 95 9.7 About the Authors 96 9.7.1 Authors 96 9.7.3 Global Director of Epidemiology and Clinical Trials Analysis 98 9.7.4 Global Head of Healthcare 99 9.8 About GlobalData 100 Table 1: The Staging of CML as Defined by Commonly Used Staging Systems 14 Table 2: Prognostic Scoring Systems for CML 15 Table 3: Common Symptoms of CML by Disease Phase 17 Table 4: Most Commonly Followed Treatment Guidelines for CML 19 Table 5: Most Prescribed First-Line Therapies for CP, AP and BP CML in the Global Markets, 2013 20 Table 6: Suggested Treatments for CML Patients with Selected BCR-ABL Kinase Domain Mutations 23 Table 7: CML Response Types, Criteria, and Corresponding Tests 24 Table 8: Leading Treatments for Chronic Myeloid Leukemia, 2013 32 Table 9: Product Profile a Gleevec 34 Table 10: Hematologic and Cytogenetic Reponses to Gleevec in Newly Diagnosed CML Patients 35 Table 11: Gleevec SWOT Analysis, 2013 37 Table 12: Product Profile a Sprycel 39 Table 13: Hematologic and Cytogenetic Reponses to Sprycel in Imatinib Resistant or Intolerant Advanced Phase CML 40 Table 14: Sprycel SWOT Analysis, 2013 42 Table 15: Product Profile a Tasigna 44 Table 16: Molecular and Cytogenetic Responses of Tasigna Compared with Gleevec in Newly Diagnosed Ph+ CML in CP 45 Table 17: Tasigna SWOT Analysis, 2013 47 Table 18: Product Profile a Bosulif 49 Table 19: Bosulif SWOT Analysis, 2013 52 Table 20: Product Profile a Iclusig 54 Table 21: Iclusig SWOT Analysis, 2013 57 Table 22: Summary of Minor Therapeutic Classes, 2013 58 Table 23: Overall Unmet Needs a Current Level of Attainment 60 Table 24: Early-stage Pipeline Projects in CML 68 Table 25: Sales Forecasts ($m) for CML Therapeutics in the United Kingdom, 2012a2022 75 Table 26: Key Events Impacting Sales of CML Therapeutics in the UK, 2013 76 Table 27: CML Market in the UK a Drivers and Barriers, 2013 76 Table 28: Key Launch Dates 89 Table 29: Key Patent Expiries 89 Table 30: Physicians Surveyed, by Country 95 List of Figures Figure 1: Translocation of Chromosomes 9 and 22 12 Figure 2: Comparison of Normal and Leukemia Blood Cells 13 Figure 3: Sales for CML Therapeutics in the UK by Brand, 2012a2022 75 Read the full report:
PharmaPoint: Chronic Myeloid Leukemia (CML) – United Kingdom Drug Forecast and Market Analysis to 2022
The only way to discover which parts to see is to visit yourself. Get packing!. Wanderlust recommends Cut Costs. Not much in London is free; state-run museums and galleries are a notable exception. The Victoria & Albert Museum, the Science Museum and the Natural History Museum are all close together, free to enter and housed in notable buildings in their own right Bath or Bristol. Ten miles up the road from snooty Bath, the City of Bristol was badly damaged in World War II and has been further spoiled by planners ever since. However it retains sections of Victorian architecture to match any in Bath, adds a link to the UK’s maritime heritage and takes itself far less seriously Forget Winter. There’s not much to recommend the UK in winter. Daylight hours are too short to enjoy outdoor sights and the weather can be foul. Don’t expect to share in the country’s most celebrated festival, Christmas: it’s very much a family affair and everything shuts Visit the ‘Celtic Triangle’. Stonehenge is one of the UK’s iconic sights, but usually busy, and the stones are fenced off. Nearby Avebury dates back to the same era and the stones, spread out by a post-card pretty village, can be explored on foot, for free. Nearby Silbury Hill completes the area’s neolithic icons Get Digging.